Wilson J A, Johnston D A, Penston J, Wormsley K G
Br J Clin Pharmacol. 1986 Jun;21(6):685-9. doi: 10.1111/j.1365-2125.1986.tb05234.x.
The inhibitory effect of ICI 162,846, a new histamine H2-receptor antagonist, on gastric secretion of acid and pepsin was studied in 10 healthy male volunteers, aged 21-30 years. Single doses of 0.5, 1.0, 2.5 and 5.0 mg were given orally at 18:00 h. Overnight 12 h gastric secretion of acid was reduced by 69, 81, 91 and 95%, respectively. The inhibition of nocturnal output of pepsin was less than acid, with median decreases of 21, 42, 73 and 87%, respectively, of the output after administration of placebo. Intragastric concentration of acid, and values of intragastric pH, during the following 12 h of the day were not significantly affected by any of the doses of the drug. We conclude that ICI 162,846 is a powerful inhibitor of gastric secretion, with potential for use in the treatment of peptic diseases.
在10名年龄在21至30岁之间的健康男性志愿者中，研究了新型组胺H2受体拮抗剂ICI 162,846对胃酸和胃蛋白酶分泌的抑制作用。于18:00口服单剂量0.5、1.0、2.5和5.0毫克。夜间12小时胃酸分泌分别减少了69%、81%、91%和95%。对夜间胃蛋白酶分泌的抑制作用小于对酸的抑制作用，与服用安慰剂后相比，中位数分别下降了21%、42%、73%和87%。给药后一天接下来的12小时内，胃酸的胃内浓度和胃内pH值均未受到任何剂量药物的显著影响。我们得出结论，ICI 162,846是一种强效的胃酸分泌抑制剂，具有用于治疗消化性疾病的潜力。
